Postępy Psychiatrii i Neurologii
eISSN: 2720-5371
ISSN: 1230-2813
Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

without publication fees

Otwarty dostęp

without publication fees
4/2025
vol. 34
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Artykuł oryginalny

From youth to late age: a comparative analysis of clinical and demographic profiles in multiple sclerosis by age at onset

Piotr T. Oleksy
1
,
Aleksandra Tobiasz
1
,
Magdalena Reclik
1
,
Ewa Góralczyk
1
,
Justyna Talaska
1
,
Zuzanna Szatkowska
1
,
Michalina Rzepka
2
,
Tomasz Chmiela
2
,
Weronika Galus
2
,
Joanna Siuda
2

  1. Students’ Scientific Association, Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
  2. Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
DOI: https://doi.org/10.5114/ppn.2025.156740
Data publikacji online: 2025/12/08
Plik artykułu:
- PPiN-00452_From_youth.pdf  [0.19 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet 2018; 391: 1622-1636.
2. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68: 1339-1342.
3. Lotti CBC, Oliveira ASB, Bichuetti DB, Castro I, Oliveira EML. Late onset multiple sclerosis: concerns in aging patients. Arq Neuropsiquiatr 2017; 75: 451-456.
4. Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol 2019; 26: 27-40.
5. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler 2020; 26: 1816-1821.
6. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-532.
7. Romero-Pinel L, Bau L, Matas E, León I, Muñoz-Vendrell A, Arroyo P, et al. The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades. Mult Scler Relat Disord 2022; 68: 104103. DOI: 10.1016/j.msard.2022.104103.
8. Habbestad A, Willumsen JS, Aarseth JH, Grytten N, Nakken KO, Myhr KM, et al. Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. J Neurol 2023; 271: 1610-1617.
9. Sıvacı AÖ, Seferoğlu M, Piri Çınar B, Göker C, Oğuz M, Karakaya G, et al. Clinical and demographic characteristics of late-onset multiple sclerosis: LOMS-TR study. Mult Scler Relat Disord 2024; 84: 105469. DOI: 10.1016/j.msard.2024.105469. 
10. Brola W, Steinborn B. Pediatric multiple sclerosis – current status of epidemiology, diagnosis, and treatment. Neurol Neurochir Pol 2020; 54: 508-517.
11. Brola W, Steinborn B, Niewada M, Mazurkiewicz-Bełdzińska M, Jóźwiak S, Sobolewski P, et al. Pediatric-onset multiple sclerosis in Poland: a registry-based retrospective cohort study. Mult Scler Relat Disord 2022; 57: 103344. DOI: 10.1016/j.msard.2021.103344.
12. Alroughani R, Akhtar S, Ahmed SF, Behbehani R, Al-Abkal J, Al-Hashel J. Incidence and prevalence of pediatric onset multiple sclerosis in Kuwait: 1994-2013. J Neurol Sci 2015; 353: 107-110.
13. Deiva K. Pediatric onset multiple sclerosis. Rev Neurol (Paris) 2020; 176: 30-36.
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
15. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840-846.
16. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the “McDonald Criteria”. Ann Neurol 2011; 69: 292-302.
17. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162-173.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
19. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases 2015; 3: 545-555.
20. D’Amico E, Patti F, Zanghì A, Chisari CG, Lo Fermo S, Toscano S, et al. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study. Eur J Neurol 2018; 25: 739-744.
21. Mirmosayyeb O, Brand S, Barzegar M, Nehzat N, Shaygannejad V, Eskandarieh S, et al. Clinical characteristics and disability progression of early- and late-onset multiple sclerosis compared to adult-onset multiple sclerosis. J Clin Med 2020; 9: 1326. DOI: 10.3390/jcm9051326.
22. Ozakbas S, Kaya E, Aslan T, Guney F, Igde H, Uzunköy G, et al. Comparative analysis of cognitive and physical characteristics in late-onset, adult-onset and early-onset multiple sclerosis patients. Mult Scler Relat Disord 2024; 90: 102469. DOI: 10.1016/j.msard.2024.105810.
23. Mouresan EF, Mentesidou E, Berglund A, McKay KA, Hillert J, Iacobaeus E, et al. Clinical characteristics and long-term outcomes of late-onset multiple sclerosis: a Swedish Nationwide Study. Neurology 2024; 102: e208051. DOI: 10.1212/WNL.0000000000208051.
24. Alroughani R, Akhtar S, Ahmed S, Behbehani R, Al-Hashel J. Is time to reach EDSS 6.0 faster in patients with late-onset versus young-onset multiple sclerosis? PLoS One 2016; 11: e0165846. DOI: 10.1371/journal.pone.0165846.
25. Ribbons KA, McElduff P, Boz C, Noyes K, Kermode AG, Taylor BV, et al. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS. Mult Scler 2018; 24: 579-586.
26. Bove RM, Healy B, Augustine A, Musallam A, Gholipour T, Chitnis T. Effect of gender on late-onset multiple sclerosis. Mult Scler J 2012; 18: 1472-1479.
27. Eskandarieh S, Sahraiain MA, Molazadeh N, Moghadasi AN. Pediatric multiple sclerosis and its familial recurrence: a population-based study (1999-2017). Mult Scler Relat Disord 2019; 36: 101377. DOI: 10.1016/j.msard.2019.101377.
28. Nasiri E, Naseri A, Talebi M. Clinical and epidemiological findings of pediatric onset multiple sclerosis in East-Azerbaijan, Iran; a population-based study. J Neurol Sci 2018; 391: 98-104.
29. Aires A, Barros A, Machado C, Viana P, Cardoso G, Soares P, et al. Diagnostic delay of multiple sclerosis in a Portuguese population. Acta Med Port 2019; 32: 289-294.
30. Patti F, Chisari CG, Arena S, Toscano S, Finocchiaro C, Fermo SL, et al. Factors driving delayed time to multiple sclerosis diagnosis: results from a population-based study. Mult Scler Relat Disord 2022; 57: 103361. DOI: 10.1016/j.msard.2021.103361.
31. Teleanu RI, Niculescu AG, Vladacenco OA, Roza E, Perjoc RS, Teleanu DM. The state of the art of pediatric multiple sclerosis. Int J Mol Sci 2023; 24: 8251. DOI: 10.3390/ijms24098251.
32. Blaschke SJ, Ellenberger D, Flachenecker P, Pöllmann W, Rommer PS, Stahmann A, et al. Time to diagnosis in multiple sclerosis: epidemiological data from the German multiple sclerosis registry. Mult Scler 2022; 28: 865-871.
33. Solomon AJ, Marrie RA, Viswanathan S, Correale J, Magyari M, Robertson NP, et al. Global barriers to the diagnosis of multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, third edition. Neurology 2023; 101: e624-e635. DOI: 10.1212/WNL.0000000000207481.
34. Nociti V, Romozzi M, Mirabella M. Challenges in diagnosis and therapeutic strategies in late-onset multiple sclerosis. J Pers Med 2024; 14: 400. DOI: 10.3390/jpm14040400.
35. Kingwell E, Leung AL, Roger E, Marrie RA, Tremlett H, Rieckmann P, et al. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci 2010; 298: 53-58.
36. Małecka I, Przybek-Skrzypecka J, Kurowska K, Mirowska-Guzel D, Członkowska A. Clinical and laboratory parameters by age for patients diagnosed with multiple sclerosis between 2000 and 2015. Neurol Neurochir Pol 2021; 55: 380-387.
37. Tremlett H, Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome? Neurology 2006; 67: 948-951.
38. Kis B, Rumberg B, Berlit P. Clinical characteristics of patients with late-onset multiple sclerosis. J Neurol 2008; 255: 697-702.
39. Bergamaschi R. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision. Expert Rev Neurother 2006; 6: 513-521.
40. Briggs FBS, Hill E, Abboud H. The prevalence of hypertension in multiple sclerosis based on 37 million electronic health records from the United States. Eur J Neurol 2021; 28: 558-566.
41. Sorensen A, Conway DS, Briggs FBS. Characterizing relapsing-remitting multiple sclerosis patients burdened with hypertension, hyperlipidemia, and asthma. Mult Scler Relat Disord 2021; 53: 103040. DOI: 10.1016/j.msard.2021.103040.
42. Moura J, Duarte S, Oliveira V, Pereira D, Costa D, Samões R, et al. Characterization of a late-onset multiple sclerosis Portuguese cohort. Mult Scler Relat Disord 2023; 70: 104506. DOI: 10.1016/j.msard.2023.104506. 
43. Awad A, Stüve O. Multiple sclerosis in the elderly patient. Drugs Aging 2010; 27: 283-294.
44. Kritsilis M, Rizou SV, Koutsoudaki PN, Evangelou K, Gorgoulis VG, Papadopoulos D. Ageing, cellular senescence, and neurodegenerative disease. Int J Mol Sci 2018; 19: 2937. DOI: 10.3390/ijms19102937.
45. McKay KA, Hillert J, Manouchehrinia A. Long-term disability progression of pediatric-onset multiple sclerosis. Neurology 2019; 92: e2764-e2773. DOI: 10.1212/WNL.0000000000007647.
46. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007; 356: 2603-2613.
47. Jakimovski D, Dujmic D, Hagemeier J, Ramasamy DP, Bergsland N, Dwyer MG, et al. Late onset multiple sclerosis is associated with more severe ventricle expansion. Mult Scler Relat Disord 2020; 46: 102588. DOI: 10.1016/j.msard.2020.102588.
48. Alkolfat F, Said S, Mekky J, Eldeeb H. What an adult multiple sclerosis registry can tell us about pediatric onset multiple sclerosis? Mult Scler Relat Disord 2023; 79: 104962. DOI: 10.1016/j.msard.2023.104962.
49. Sanai SA, Saini V, Benedict RH, Zivadinov R, Teter BE, Ramanathan M, Weinstock-Guttman B. Aging and multiple sclerosis. Mult Scler J 2016; 22: 717-725.
50. Chitnis T, Aaen G, Belman A, Benson L, Gorman M, Goyal MS, et al. Improved relapse recovery in pediatric compared to adult multiple sclerosis. Brain 2020; 143: 2733-2741.
51. Harding KE, Liang K, Cossburn MD, Ingram G, Hirst C, Pickersgill T, et al. Long-term outcome of pediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2013; 84: 141-147.
52. Spelman T, Magyari M, Piehl F, Podda J, Rasmussen PV, Sellebjerg F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol 2021; 78: 1197-1204.
53. Naseri A, Nasiri E, Sahraian MA, Daneshvar S, Talebi M. Clinical features of late-onset multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 2021; 50: 102816. DOI: 10.1016/j.msard.2021.102816.
54. Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 2017; 8: 577. DOI: 10.3389/fneur.2017.00577.
55. Buscarinu MC, Reniè R, Morena E, Romano C, Bellucci G, Marrone A, et al. Late-onset MS: disease course and safety-efficacy of DMTS. Front Neurol 2022; 13: 829331. DOI: 10.3389/fneur.2022.829331.
56. Hillert J, Magyari M, Soelberg Sørensen P, Butzkueven H, Van Der Welt A, Vukusic S, et al. Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network. Front Neurol 2021; 12: 647811. DOI: 10.3389/fneur.2021.647811.
57. Marriott JJ, Ekuma O, Fransoo R, Marrie RA. Switching to second-line MS disease-modifying therapies is associated with decreased relapse rate. Front Neurol 2023; 14: 1243589. DOI: 10.3389/fneur.2023.1243589.
58. Seifer G, Arun T, Capela C, Laureys G, Jones E, Dominguez-Castro P, et al. Influence of physicians’ risk perception on switching treatments between high-efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosis. Mult Scler Relat Disord 2023; 76: 104770. DOI: 10.1016/j.msard.2023.104770.
59. Bartosik-Psujek H, Adamczyk-Sowa M, Kułakowska A, Głażewska J, Smaga A, Brola W. Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment. Postep Psychiatr Neurol 2023; 32: 59-67.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). License allowing third parties to download and share its works but not commercially purposes or to create derivative works.
Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Mednauka Aktualności Czasopisma Książki eBooki Konferencje i webinary Podcasty
Serwisy
KONGRES TOP MEDICAL TRENDS Menedżer Zdrowia Lekarz POZ Choroby rzadkie Dermatologia Diabetologia Onkologia Neurologia Reumatologia Gastroenterologia Pulmonologia Ginekologia Kurier Medyczny Zalecenia i rekomendacje e-Praktyka Leczenia Ran Warto wiedzieć
e-Akademia
e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń Akademia GLP-1
© 2025 Termedia Sp. z o.o.
Developed by Bentus.